AKT family and miRNAs expression in IL-2 induced CD4\(^+\)T cells

Najmeh Ranji, Majid Sadeghizadeh, Morteza Karimipoor, Mohammad Ali Shokrgozar, Reza Ebrahimzadeh-Vesal

**Abstract**

**Objective(s):** Study of non-coding RNAs is considerable to elucidate principal biological questions or design new therapeutic strategies. miRNAs are a group of non-coding RNAs that their functions in PI3K/AKT signaling and apoptosis pathways after T cell activation is not entirely clear. Herein, miRNAs expression and their putative targets in the mentioned pathways were studied in the activated CD4\(^+\)T cells.

**Materials and Methods:** Herein, proliferation rate and IL-2 secretion were measured in treated and untreated cells by IL-2. Putative targets of up-regulated miRNAs were predicted by bioinformatics approaches in the apoptotic and PI3K/AKT signaling pathways. Then the expression of two putative targets was evaluated by quantitative RT-PCR.

**Results:** Proliferation rate of treated cells by IL-2 increased in a dose- and time-dependent manner. Naive and activated CD4\(^+\)T cells induced by different dose of IL-2 secreted abundant amounts of IL-2. Also, in IL-2 un-induced cells (IL-2 depleted cells) after 3 days, decrease of proliferation has been shown. In silico analysis predicted putative targets of up-regulated miRNAs such as AKT1, AKT3 and apoptotic genes in the activated cells induced or un-induced by IL-2. Decrease of AKT3 was shown by Q-RT-PCR as a potential target of miRNAs overexpressed in IL-2 depleted cells. But there was no significant difference in AKT1 expression in two cell groups.

**Conclusion:** Our analysis suggests that decrease of AKT3 was likely controlled via up-regulation of specific miRNAs in IL-2 depleted cells. Also it seems that miRNAs play role in induction of different apoptosis pathways in IL-2 induced and un-induced cells.

**Introduction**

Protein kinase B (AKT/PKB) is a family including three kinases (AKT1/PKB\(\alpha\), AKT2/PKB\(\beta\), AKT3/PKB\(\gamma\)) which play role in cellular functions such as cell survival, metabolism, differentiation and proliferation (1). These isofoms have similar domains in protein structure and are phosphorylated by PI3K (2). In respect to important role of PI3K/AKT pathway in cell survival, these genes are considerable targets for cancer therapy and inflammatory suppression (3). It has been shown that PI3K/AKT pathway is necessary for T cell proliferation (4). IL-2/IL-2R binding activates PI3K/AKT pathway and phosphorylates AKT/PKB (5, 6). Akt activation leads to up-regulation of Bcl-2 and c-myc which inhibit apoptosis and increase cell target genes through mRNA degradation or translational repression (12). Dysregulation of miRNAs have been found in various cancers (13-17), neurological disorders, metabolic (18) and immune proliferation (6). Also, AKT/PKB phosphorylates GSK3, which in turn leads to export NFAT into T cell nucleus. NFAT and AP-1 (Fos/Jun) proteins in the nucleus bind to promoter of target genes such as IL-2 and induce cell proliferation (7). However, regulation of Akt family and its anti-apoptotic properties in T cell after TCR-engagement and IL-2 induction has remained unknown.

MicroRNAs (miRNAs) are small non-coding RNAs by ~22 nucleotide length (8) that play critical roles in biological and physiological processes (9). More than 700 miRNAs have been determined in the mammalian cells (10) that potentially regulate expression of about one-third of mRNAs (11). miRNAs bind to target mRNAs with perfect or imperfect complementarity and then suppress target genes through mRNA degradation or translational repression (12). Dysregulation of miRNAs have been
found in various cancers (13-17), neurological disorders, metabolic (18) and immunesystem diseases (19, 20). miRNAs are important negative regulators in the different cells which can change expression of target genes promptly. In this respect, it appears that they can be promising therapeutic candidates for disorders in immune system, that requires precise and prompt modulation through complex signaling networks.

In our previous study, miRNA profiling was performed by a reproducible and high sensitive method (8) using miRNA Q-PCR array. Herein, bioinformatics prediction revealed that deregulated miRNAs in activated T cells after IL-2 induction or depletion target different genes involved in PI3K/AKT signaling as well as apoptotic pathways. Also, AKT1 and AKT3 expression were investigated as two putative targets of modulated miRNAs in the cell groups.

Materials and Methods

Cell culture
Human naïve CD4+T cells isolated from PBMC were cultured in DMEM supplemented with 10% FBS and antibiotics. Naïve CD4+T cells (1 × 10⁵ cells/well) were seeded in 96-well plates and activated with/without anti-CD3, CD2, CD28 microbeads (bead-to-cell ratio 1:2). After 3 days, different doses of IL-2 (0.375, 0.75 and 1.5 ng/ml, R&D Systems, Minneapolis, MN) were added for 24, 48 and 72 hr. Cell numbers were determined by trypan blue exclusion assay. Cells were grown at 37°C and 10% CO₂ in humidified air. Percentage of CD4+CD45RA- T cells after culture was identified by flow cytometry using anti-human CD4-FITC (RPA-T4; eBiosciences) and anti-human CD45RA-PE (JS-83). Mouse IgG1k-FITC and mouse IgG1k-PE were served as isotype controls. All mAb were purchased from eBiosciences (San Diego, CA, USA). Anti-human-CD2, CD3, CD28 microbeads (human T Cell Activation/Expansion Kit, Miltenyi Biotec GmbH) were a gift from Dr Kambiz Arasteh (asthma and allergy center, Imam Khomeini Hospital, Tehran, Iran).

BrdU assay
The BrdU procedure was carried out according to the manufacturer’s instructions (Roche applied biosciences). Briefly, 10 μM BrdU labeling solution was added to each well for 18 hr. The microplate contents were centrifuged (1000 rpm, 10 min) and cells were dried using a hair dryer for 20 min. Cell fixation and DNA denaturing were performed with FixDenat solution for 30 min. After removing the solution, cells were incubated with anti-BrdU mAbs conjugated to peroxidase for 3 hr at room temperature. After washing, the reaction was started by adding substrate solution and then stopped after 3 min by adding 1 M H₂SO₄ solution. The optical density was measured at 450 nm with a reference wavelength at 630 nm using an ELISA plate reader.

Cell proliferation ELISA, and BrdU (colorimetric) kit (Roche Applied Science, Mannheim, Germany) was a gift from Dr Mehdi Mahdavi (Virology department, Pasteur Institute, Iran).

IL-2 secretion assay
After treatment with IL-2 for 24, 48 and 72 hr, cell-free supernatants were harvested and kept frozen (-80°C) until assayed. IL-2 concentrations were determined by commercially available ELISA kit (Human IL-2 ELISA Ready-SET-Go Kit, eBiosciences) following the manufacturer’s protocol. The test sensitivity was 4 pg/ml. The absorbance was measured at 450 nm test wavelength and 545 nm reference wavelengths using an ELISA plate reader. Cytokine quantities in the samples were calculated from standard curves of recombinant cytokines using a regression linear method.

Investigation of potential targets of deregulated miRNAs
In the present study, we carried out miRNA profiling in IL-2 induced and depleted CD4⁺ T cells (data not shown). Then, targets of up-regulated miRNAs were predicted by bioinformatics tools in PI3K/AKT and apoptotic signaling pathways. To predict potential targets of most modulated miRNAs, Targets can (http://www.targetscan.org/), Diana mT (http://diana.cslab.ece.ntua.gr/), miRanda (http://www.microrna.org/), miRWalk (http://wwwumm.uni-heidelberg.de/apps/zmf/mirwalk/), and miRDB (http://mirdb.org/cgi-bin/search.cgi) algorithms were used.

AKT1 and AKT3 expression analysis by Q-RT-PCR
To evaluate our predictions, we investigated AKT1 and AKT3 expression as potential targets of some modulated miRNAs by Q-RT-PCR. cDNA synthesis was carried out using total RNA with Prime Script Reverse Transcriptase (Takara bio inc. Japan) according to the manufacturer’s instructions. Quantitative PCR (Q-PCR) was performed with Power SYBR® Green PCR Master Mix (ABI applied biosystems) using Applied Biosystems Step One™ instrument. PCR programs were as follows: 95°C for 10 min, 40 cycles at 95°C for 15 sec and 60°C for 1 min. GAPDH gene was used as an endogenous internal control. Primer sequences were shown as follow: AKT1 (160 bp) Forward: 5’-GGTGGCCAGGACGAGTG-3’; Reverse: 5’-AACGATTGAAGAAGACCTGC-3’, AKT3 (118bp) Forward: 5’-TTGGTACCGTGATCTCAAGTTGG-3’, Reverse: 5’-GAAGGTCTTCTATGGTGGCTGC-3’ GAPDH (226 bp) Forward: 5’-GAAGGTAGTCGGAGATATC-3’ and Reverse: 5’-GAAGATGGTG
Figure 1. Proliferation analysis by BrdU incorporation (ELISA) assay. Optical density (OD) of treated and un-treated cells by anti-CD2, CD3, CD28 and/or IL-2 revealed the most proliferative rate in activated cells after IL-2 induction during 3 days. Significant difference (P < 0.0001 by one-way ANOVA) in the proliferation rate between IL-2 induced cells and activated ones with un-treated cells was statically measured. Representative data from at least three experiments are shown. The results are presented as mean ± SD.

ATGGGATTTC-3'. All reactions were run in triplicate and the results were analyzed with ∆∆C_T method. Relative expression of gene was calculated by the equation 2−∆∆CT.

Statistical analysis
Results are presented as mean ±SD. Student's t-test or One-Way ANOVA test was used to compare data between two cell groups. Individual experiments were performed in triplicate.

Results
Cell proliferation and IL-2 secretion
Following exposure to anti-CD2/CD3/CD28 for 72 hr, the CD4+CD45RA+ T cells formed large cell colonies which revealed T cell activation (data not shown). The activated and un-activated CD4+ T cells were induced by different doses of exogenous IL-2 during other 3 days. IL-2 could not induce cell proliferation in un-activated cells; but, in the activated cells, the increase of optical density (OD) after IL-2 treatment has been shown (Figure 1). Also, flow cytometric analysis showed that the percentage of CD4+CD45RA+ T cells declined after stimulation with both microbeads and IL-2 (Figure 2) compared to stimulation with microbeads alone, which is likely result of the differentiation of some of the activated CD4+T cells after IL-2 induction. In addition, the amount of secreted IL-2 in supernatant was determined between ~1000 to1200 pg/ml in activated and un-activated cells after stimulation with exogenous IL-2. But in cells treated by microbeads alone (activated cells) and in un-treated cells (naïve CD4+ T cells), secretion of IL-2 was not determined by ELISA during 3 days (Figure 3). According to these results, IL-2 depletion occurred in CD4+ T cells after full-activation during next 3 days. This cell group herein was used as control and it is called "IL-2 depleted cells".

Quantitative analysis of miRNAs potential targets
To explain biologic roles of deregulated miRNAs (data not shown) after T cell activation and IL-2 induction, their potential targets were identified by in silico analysis. Diana miRpath analysis revealed that modulated miRNAs potentially target several cell signaling pathways such as TCR-, IL-2-, PI3K/AKT-, and MAPK/ERK- signaling and apoptotic pathways. In addition, putative targets of up-regulated miRNAs were predicted by other algorithms (Table 1). For example, AKT1 was a potential target of modulated miRNAs in both IL-2 induced and depleted cells. Whereas AKT3 was target of greater number of miRNAs in IL-2 depleted cells than IL-2 induced cells. Also, anti-apoptotic and pro-apoptotic genes such as BCL2 and BCL2L11 (Bim) were target of up-regulated miRNAs. Of these targets, we investigated expression levels of AKT1 and AKT3 by Q-RT-PCR. As expected, down-regulation of AKT3 (Figure 4), has been shown in IL-2 depleted cells. While, there was no significant difference in AKT1 expression levels between two cell groups.
Table 1. Potential targets of the most modulated miRNAs in two cell groups predicted by algorithms such as TargetScan, miRanda, Diana microT and miRWalk

| Upregulated miRNAs in IL-2 depleted cells | Target genes                                                  | Upregulated miRNAs in IL-2 induced cells | Target genes                                                  |
|------------------------------------------|---------------------------------------------------------------|------------------------------------------|---------------------------------------------------------------|
| has-miR-342-3p                           | AKT2, BCL2L1, CREB1, GSK3, BCL2L1[1](Bim), CYCS              | has-miR-634                              | AKT2, CYCS, BCL2L1, PUMA, BCL2L1                              |
| has-miR-942                              | AKT1, AKT3, APAF1, FAS, GSK3, CYCS, BCL2, FASL               | has-miR-192*                            | PIM1, CYCS                                                   |
| has-miR-92a-2*                           | AKT1, AKT2, AKT3, APAF1, CYCS                                | has-miR-595                             | APAF1, CYCS, BCL2L1, GSK3, BCL2L1, BCL2                     |
| has-miR-328                              | AKT1, AKT3, PIM1, APAF1, CYCS, AKT2, BCL2L1 [BCL-3L], GSK3, NOXA, PUMA, BCL2L1 | has-miR-580                            | PIM1, CYCS, CREB1, NFKB2, BCL2L1                           |
| has-miR-766                              | MDMA1, PIM1, APAF1, CYCS, AKT2, BCL2L1, DR5, FAS, GSK3, PUMA, BCL2L1 | has-miR-941                            | AKT1, GSK3                                                   |
| has-miR-98                            | APAF1, BCL2L1, GSK3, CDKN1A (p21), BCL2L1                   | has-miR-586                             | AKT1, APAF1, CREB1, BCL2L1, CYCS, BCL2, FASL               |
| has-miR-106a                             | AKT3, MDMA1, APAF1, CYCS, BCL2L1, CREB1, DR5, GSK3, CDKN1A, BCL2L1, BCL2, FASL | has-miR-558                             | AKT2, AKT3, PIM1, APAF1, BCL2L1, CREB1, GSK3, CDKN1A, BCL2L1, BCL2 |
| has-miR-501-3p                           | AKT1, AKT3, APAF1, AKT2, NOXA, FASL                          | has-miR-487a                            | AKT2, CYCS, DR5, FAS, NOXA, AKT3, J-2, FASL                |
| has-miR-304*                            | AKT2, AKT3, PIM1, APAF1, CREB1, CYCS, FASL                    | has-miR-520f                            | AKT1, AKT2, AKT3, MDMA1, CREB1, DR5, GSK3, CDKN1A, BCL2L1, FASL |
| has-miR-590-5p                           | APAF1, CREB1, DR5, BCL2, FASL                                | has-miR-181c*                           | AKT2, AKT3, PIM1, CREB1, MDMA1, APAF1, BAX, DRS5, GSK3, NOXA, BCL2L1 | |
| has-miR-20a                             | MDMA1, CREB1, DR5, FAS, GSK3, CDKN1A, NOXA, BCL2L1, BCL2, FASL | has-miR-548c-5p                          | AKT2, DR5, GSK3, NOXA, BCL2L1, BCL2                         |
| has-miR-192                             | PIM1, CYCS, CREB1, GSK3, BCL2L1, FASL                        | has-miR-886-3p                          | AKT1, AKT2, AKT3, MDMA1, GSK3, CDKN1A, BCL2L1, PUMA, BCL2L1  |
| has-miR-16-2*                           | AKT3, CYCS, FASL                                              | has-miR-665                             | AKT1, AKT2, AKT3, GSK3, CDKN1A, BCL2L1                      |
| has-miR-425*                            | PIM1, CYCS                                                   | has-miR-512-3p                           | AKT1                                                       |
| has-miR-338-5p                           | AKT3, NFKB1, APAF1, CREB1, DR5, GSK3, BCL2L1, BCL2L1, FASL |                                                  |                                                             |
| has-miR-23a                             | AKT2, APAF1, CYCS, DR5, FAS, NOXA, BCL2L1, BCL2               |                                                  |                                                             |
| has-miR-222                             | AKT2, MDMA2, APAF1, CYCS, PUMA, BCL2L1, BCL2, FASL            |                                                  |                                                             |
| has-miR-20a*                            | AKT2, AKT3, BCL2L1, CYCS, FASL                               |                                                  |                                                             |
| has-miR-93                              | AKT3, APAF1, CYCS, CREB1, FAS, GSK3, NOXA, BCL2L1, BCL2, FASL |                                                  |                                                             |
| has-miR-155                             | APAF1, CREB1, DR5, BCL2                                       |                                                  |                                                             |
| has-miR-218                             | AKT3, CYCS, CREB1, DR5, GSK3                                 |                                                  |                                                             |
| has-miR-374a                            | AKT1, AKT3, MDMA2, APAF1, CYCS, FAS, GSK3, NOXA              |                                                  |                                                             |
| has-miR-532-5p                           | AKT3, MDMA2, CYCS, DR5                                       |                                                  |                                                             |
| has-miR-130b                            | AKT2, APAF1, CREB1, DR5, GSK3, CDKN1A, PUMA, BCL2L1           |                                                  |                                                             |
| has-miR-215                             | PIM1, CREB1, GSK3, BCL2L1                                   |                                                  |                                                             |
| has-miR-888                             | AKT2, AKT3, APAF1, CREB1, FAS, CDKN1A, BCL2L1                |                                                  |                                                             |
| has-miR-330-3p                           | AKT2, AKT3, APAF1, DR5, FAS, GSK3, NFKB1, BCL2L1             |                                                  |                                                             |
| has-miR-185*                            | AKT1, AKT2, PIM1, CDKN1A                                     |                                                  |                                                             |
| has-miR-371-3p                           | AKT2, GSK3, CDKN1A                                           |                                                  |                                                             |
| has-miR-32                              | DR5, GSK3, BCL2L1, FASL                                      |                                                  |                                                             |
| has-miR-105                             | AKT1, AKT2, AKT3, CREB1, GSK3, CDKN1A, BCL2L1                |                                                  |                                                             |
| has-miR-195                             | AKT2, AKT3, DR5, FAS, CDKN1A, BCL2L1                         |                                                  |                                                             |
| has-miR-323-5p                           | FAS, GSK3, CDKN1A                                            |                                                  |                                                             |
| has-miR-513a-3p                          | MDMA1, PIM1, CREB1, FAS, GSK3                                |                                                  |                                                             |
| has-miR-520a-3p                          | AKT1, AKT2, CREB1, DR5, GSK3                                |                                                  |                                                             |
| has-miR-130b*                           | PIM1, CREB1, FASL                                            |                                                  |                                                             |
| has-miR-548h                            | AKT3, MDMA2, APAF1, DR5, GSK3, NFKB1, NOXA                    |                                                  |                                                             |
| miRNA | Target Genes |
|-------|--------------|
| hsa-miR-561 | AKT2, AKT3, CREB1, DR5, FAS, GSK3, NOXA, CDKN1A, BCL2L11 |
| hsa-miR-589* | AKT3, PIM1, FAS, GSK3 |
| hsa-miR-34b* | AKT3, PIM1, CREB1 |
| hsa-miR-424* | AKT1, AKT3, PIM1 |
| hsa-miR-517c | FASL |
| hsa-miR-607 | AKT2, AKT3, PIM1, CREB1, BCL2, IL-2, FASL |
| hsa-miR-379 | APAF1, BCL2L1, GSK3 |
| hsa-miR-1236 | AKT3, PIM1, APAF1, CREB1, GSK3, PUMA, DR5 |
| hsa-miR-486-5p | APAF1, BCL2L1, GSK3 |
| hsa-miR-148b | AKT3, CREB1, CDKN1A, PUMA, PUMA, BCL2L11 |
| hsa-miR-181a | AKT2, AKT3, CREB1, FAS, GSK3, NOXA, BCL2L11, BCL2, IL-2, FASL |
| hsa-miR-211 | AKT2, APAF1, CREB1, BCL2L1, GSK3 |
| hsa-miR-249b | GSK3 |
| hsa-miR-24 | AKT2, AKT3, MDM2, Pim1, APAF1, CREB1, GSK3, PUMA, BCL2L11, BCL2, FASL |
| hsa-miR-200c | AKT2, AKT3, CREB1, NOXA |
| hsa-miR-548b-3p | AKT2, MDM2, CREB1, FASL |
| hsa-miR-150 | AKT2, AKT3, PIM1, APAF1, Bax, CREB1, PUMA |
| hsa-let-7i | AKT1, AKT2, PIM1, FASL |
| hsa-miR-23b | APAF1, AKT2, DR5, FAS, GSK3, NOXA, BCL2 |
| hsa-miR-21 | DR5, APAF1, BCL2, FASL |
| hsa-miR-1260 | AKT2, DR5, GSK3, PUMA |
| hsa-miR-31 | Pim1, GSK3 |
| hsa-miR-92a | MDM2, CREB1, DR5, GSK3, BCL2L11, FASL |
| hsa-miR-200b* | DR5, AKT2, AKT3 |
| hsa-miR-744* | AKT1, AKT2, AKT3 |
| hsa-miR-324-5p | GSK3, PUMA |
| hsa-miR-151-5p | AKT2, MDM2, GSK3 |
| hsa-miR-25 | AKT2, MDM2, APAF1, DR5, FAS, GSK3, BCL2L11, FASL |
| hsa-miR-940 | AKT2, MDM2, APAF1, Bax, DR5, GSK3, CDKN1A, PUMA |
| hsa-miR-197 | AKT2, NOXA, BCL2 |
| hsa-miR-501-5p | AKT3, NFKB2 |
| hsa-miR-181b | AKT2, AKT3, DR5, FAS, GSK3, NOXA, BCL2L11, BCL2, IL-2, FASL |

**Figure 3.** IL-2 production was measured in the supernatants of cultured cells during 3 days after IL-2 induction by ELISA. Cytokine production was significantly higher in the cultures from IL-2 treated cells compared to activated or un-treated cells (*P*<0.0001 by t-test). It is noticeable that cytokine secretion by un-treated CD4+CD45RA+ T cells and activated cells (by microbeads) was not detectable. Representative data from at least three experiments are shown. The results are represented as mean ±SD.
Discussion

miRNA profiling is an important approach to identify expression of miRNAs in the biological and physiological processes. The expression pattern of miRNAs in different cells allow to determine relation between transcriptome and microRNome. To investigate miRNAs involved in proliferation or death in IL-2 induced CD4⁺ T cells after miRNA profiling, potential targets of up-regulated miRNAs were analyzed in PI3K/AKT and apoptotic pathways. To investigate the effects of IL-2 on T cell proliferation, the first naïve CD4⁺ T cells were induced by different doses of IL-2. Exogenous IL-2 stimulated IL-2 secretion in naïve CD4⁺ T cells, while cell proliferation was not induced in the cells. Therefore, naïve CD4⁺ T cells were activated by anti-CD2, CD3, CD28 microbeads to express IL-2-Rα chian. TCR stimulation by Ag (21), Anti-CD3, or CD28 induces IL-2-Rα expression on T cell surface. Subsequently, IL-2 binds to IL-2 receptor (α, β and γ chains) and induces cell proliferation by activating downstream signaling pathways (21). The activated cells then were cultured with/without exogenous IL-2 for 3 days and the expression pattern of miRNAs deregulated after IL-2 induction was determined by Q-RT-PCR. IL-2 is a crucial growth factor for Ag-primed T cells that regulates cell survival and death via several downstream pathways including JAK/STAT and PI3K/AKT signaling (5). Previous studies have determined anti-apoptotic role of Akt/PKB family in IL-2 induced T cells; but, the expression pattern of AKT family and miRNAs and their relation to cell proliferation or death in these cells has not been sought, herein we investigated expression of two members of Akt family (AKT1 and AKT3) which potentially targeted by up-regulated miRNAs in IL-2 induced and depleted cells.

In IL-2 un-induced activated cells, depletion of IL-2 during 3 days indicated that these cells have a similar process to end immune response. In murine activated cells, decline of IL-2 during 48 hr after activation has been shown (22). In this study, IL-2 depletion led to decrease of proliferation on day 3 compared to day 2 in the activated CD4⁺ T cells. With IL-2 withdrawal, the full-activated T cells slowly undergo apoptosis (26). While, IL-2 induction led to secretion of IL-2 in activated cells and increase of proliferation and survival during 3 days, that is similar to progression of immune response. PI (propidium iodide) staining in our previous study has revealed to increase apoptosis after 3 days in IL-2 depleted cells relative to IL-2 induced ones (23). In other studies, it has been shown that to maintain lymphocyte homeostasis (24), apoptosis happens after activation of regulatory T cells (Treg cells) (25) or after IL-2 depletion (in vitro) (22, 26). This result indicates that the absence or presence of a specific cytokine is determinant for immune cells destination. The IL-2 depleted cells herein suffered greater apoptosis than IL-2 induced cells. Thus, it is noticeable that over-expression of pro-apoptotic genes and/or under-expression of anti-apoptotic genes occur in the IL-2 depleted cells.

miRNAs regulate some aspects of immune responses, and their expression changes during T cell activation and differentiation (10, 27, 28). The role of some miRNAs that were up-regulated in IL-2 depleted cells such as miR-181a and miR-21 has been previously determined in T cell response or development. For example, miR-181a regulates T cell sensitivity to antigens by down-modulation of multiple phosphatases. Thus, miR-181a down-modulation in IL-2 induced cells likely increases the activation of these phosphatases to repress TCR/Ag engagement. Naïve T cells derived from miR-155 knockout mice were revealed greatly trend to Th2 rather than Th1 differentiation (10), miR-21 is induced after TCR stimulation and likely is a negative regulator of TCR signaling, and ectopic expression of miR-21 decreases T cell activation (29). Increase of apoptosis in IL-2 depleted cells is associated with proliferation related pathways such as TCR- and IL-2 signaling. Thus, miR-21 over-expression in these cells likely led to suppress T cell activation by inhibition of TCR signaling. It appears that mentioned miRNAs after IL-2 depletion inhibit clonal expansion through regulation of TCR and IL-2 signaling. Also they may drive T cell to differentiation or apoptosis. In this study, bioinformatics tools predicted that greater number of up-regulated miRNAs such as hsa-miR-942, hsa-miR-92a-2*, hsa-miR-328, hsa-miR-330-3p and hsa-miR-374a potentially targeted AKT3 gene in IL-2 depleted cells. While, AKT1 was potentially targeted by up-regulated miRNAs in both IL-2 induced and depleted cells. AKT family members are differentially expressed during T cell development (2). Previously, it is defined that in the absence of Akt1, immature T cell suffers increased apoptosis (2). Herein, AKT1

Figure 4. Quantitative expression of AKT1 and AKT3 in IL-2 induced cells compared to IL-2 depleted ones. Relative expression of AKT1 and AKT3 was normalized to GAPDH. Representative data from at least three experiments are shown. Asterisks indicate significant differences the groups (* P <0.05). The results are represented as mean ±SD.
expression was approximately at the same levels in two cell groups; so, it is suggested that Akt1 is important for survival of activated cell both in the presence and absence of IL-2. Also, it is reasonable that Akt1 expression was required for cell proliferation in activated cells, but it seems that Akt1 could not efficiently repress cell death due to IL-2 depletion; so that three days after T cell full-activation apoptosis overcame proliferation. Also, it is possible that anti-apoptotic effects of Akt1 were reduced by over-expression of apoptotic genes in the IL-2 depleted cells. On the other hand, we revealed that induction of IL-2 in the activated cells increased AKT3 expression and cell proliferation. Akt3 role has been determined in tumorigenesis and inhibition of apoptosis (30). Akt3 activates many oncogenic pathways including CREB, IKK, Cyclin D1 and PRAS40 (31), also it inhibits FoxO3a protein as an apoptotic inducer (32). Regarding Akt3 was a putative target of most up-modulated miRNAs in IL-2 depleted cells; it appears that down-regulation of AKT3 after IL-2 depletion may be regulated by miRNAs, partly. Also, increase of AKT3 after IL-2 induction likely plays role in the cell survival and decrease of apoptosis. In a study on MEF-Akt1, and 2-DKO cells, it has been determined that apoptosis significantly induced only after depletion of ≥ 80% Akt3 protein in these cells. It was considerable that reintroducing Akt3 inhibited apoptosis in these cells (33). However, herein in the IL-2 induced cells AKT1 was down-modulated, but it seems that because of AKT3 up-modulation IL-2 induced cells suffered apoptosis less than IL-2 depleted cells. While, decrease of AKT3 and AKT1 together induced greater apoptosis in IL-2 depleted cells. Nevertheless, it is unclear yet why AKT1 or AKT3 were expressed differentially after T cell activation.

Regarding Akt signaling pathway is one of the main pathways implicated in cell survival (34), but no evidence has yet been reported that Akt inhibits pro-apoptotic protein such Bad or Fasl in T cells. However, it seems that Akt plays role in the up-regulation of anti-apoptotic proteins including Bcl-2 and Bcl-xl (35). T cell apoptosis is induced either through intrinsic mitochondrial (result of antigen clearance and IL-2 withdrawal) or extrinsic (FAS mediated) pathway (36, 37). In this study, under-expression of Bcl-2, as a potential target of up-regulated miRNAs, was determined after IL-2 withdrawal (depletion) (data not shown). Over-expression of Bcl-2 inhibits intrinsic pathway (38). Previously, it has been shown that Bcl-2 expression decreased after IL-2 depletion in CD4+ T cells blasts (39). Up-regulated miRNAs in IL-2 depleted cells may regulate intrinsic pathway by Bcl-2 targeting. Also, cytokine withdrawal apoptosis (CWA) is regulated by the pro-apoptotic members of Bcl-2 family such as Bim and Puma. These members activate pro-apoptotic proteins Bak and Bax (37). Herein, in silico analysis predicted that Bim (BCL2L11) was potentially targeted by up-regulated miRNAs both in IL-2 depleted and induced cells. It is suggested that Bim may be controlled at post-transcriptional level partly after T cell activation or IL-2 induction.

It has been reported that Akt attenuates activation of intrinsic pathway through inhibition of Bak and Bax (40). Thus in IL-2 induced cells, apoptosis probably was inhibited by Akt activity, but in IL-2 depleted cells, decrease of AKT3 expression may have influence on increase of pro-apoptotic proteins. Other studies have revealed that activated Akt inhibits the intrinsic pathway of apoptosis (40). Akt3 likely plays role as an inhibitor in mitochondrial apoptosis pathway in IL-2 depleted T cells (26); in addition, decrease of AKT3 along with up-regulation of miRNAs likely led to activation of apoptosis intrinsic pathway. While in IL-2 induced cells it has been demonstrated that FASL signaling plays role in extrinsic apoptosis induction (26).

Conclusion

According to our results, it seems that IL-2 depletion leads to over-expression of miRNAs that play role in induction of apoptosis and inhibition of proliferation. However, IL-2 induction likely increases expression of miRNAs involved in cell death inhibition. On the other hand, AKT3 may be important for survival of IL-2 induced cells that its expression is regulated by miRNAs in part. Our findings suggested that up-regulated miRNAs likely regulate activation of apoptosis pathway after IL-2 depletion by suppression of anti-apoptotic genes such as Akt family and Bcl-2.

Conflict of interests

The authors declare no conflicts of interest.

Acknowledgment

Hereby, we thank Iran National Science Foundation for providing the project costs. Also, we appreciate the colleague of Cell Bank at Pasteur Foundation for providing the cell line. Also, we thank Dr Amir Amanzadeh, Dr Keyhan Azadmanesh and Dr Sara Soudi for helpful discussions and technical assistance.

References

1. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schwerer S, Zacharioudaki V, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009; 31:220-231.
2. Juntilla MM, Woford JA, Birnbaum MJ, Rathmell JC, Koretzky GA. Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. Proc Natl Acad Sci USA 2007; 104:12105-12110.
3. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115:2618-2624.
4. Lockyer HM, Tran E, Nelson BH. STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J Immunol 2007; 179:5301-5308.
5. Fung MM, Rohwer F, McGuire KL. IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell Signall 2003; 15:625-636.
6. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A 1997; 94:3627-3632.
7. Bauer B, Baier G. Protein kinase C and AKT/protein kinase B in CD4+ T-lymphocytes: new partners in TCR/CD28 signal integration. Mol Immunol 2002; 38:1087-1099.
8. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009; 136:26-36.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-866.
10. Lindsay MA. microRNAs and the immune response. Trends Immunol 2008; 29:343-351.
11. Furer V, Greenberg JD, Attur M, Abramson SB, Pillinger MH. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010; 136:1-15.
12. Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Sarkar FH. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2010; 292:141-148.
13. Sonkoly E, Stahle M, Pivarski A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 2008; 18:131-140.
14. Molnar V, Tamasi V, Bakos B, Wiener Z, Falus A. Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin Cancer Biol 2008; 18:111-122.
15. Gartel AL, Kandel ES. miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol 2008; 18:103-110.
16. Babashah S, Sadeghizadeh M, Hajjafathali A, Tavirani MR, Zomorod MS, Ghadiani M, et al. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ stem/progenitor cells. Int J Cancer 2013; 133:579-589.
17. Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr) 2012; 35:317-334.
18. Tili E, Michaille JJ, Calvin GA. Expression and function of micro-RNAs in immune cells during normal or disease state. Int J Med Sci 2008; 5:73-79.
19. Almeida MI, Reis RM, Calvin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 2011; 717:1-8.
20. Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 2011; 157:163-179.
21. Du J, Yang H, Zhang D, Wang J, Guo H, Peng B, et al. Structural basis for the blockade of IL-2 signaling by therapeutic antibody basiliximab. J Immunol 2010; 184:1361-1368.
22. Shu L, Yin W, Zhuang H, Hua Z. Comparison of gene expression profiles in mouse primary T cells under normal and prolonged activation. Blood Cells Mol Dis 2006; 37:64-75.
23. Ranji N, Sadeghizadeh M, Shokrgozar MA, Bakhtshande B, Karimipour M, Amanzadeh A, et al. MiR-17-92 cluster: an apoptosis inducer or proliferation enhancer. Mol Cell Biochem 2013; 380:229-238.
24. Jolly C, Sattentau QJ. Regulated secretion from CD4+ T cells. Trends Immunol 2007; 28:474-481.
25. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21:1105-1111.
26. Hieronymus T, Blank N, Gruenke M, Winkler S, Haas JP, Kalden JR, et al. CD 95-independent mechanisms of IL-2 deprivation-induced apoptosis in activated human lymphocytes. Cell Death Differ 2000; 7:530-547.
27. Tsitsiou E, Lindsay MA. microRNAs and the immune response. Curr Opin Pharmacol 2009; 9:514-520.
28. Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9:839-845.
29. Carissimi C, Fulci V, Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 2009; 8:520-524.
30. Madhunapantula SV, Desai D, Sharma A, Huh SJ, Amin S, Robertson GP. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol Cancer Therapeutics 2008; 7:1297-1308.
31. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmaco 2010; 80:624-637.
32. Matheny RW, Jr, Adamo ML. Role of Akt isoforms in IGF-I-mediated signaling and survival in myoblasts. Biochem Biophys Res Commun 2009; 389:117-121.
33. Liu X, Shi Y, Birnbaum MJ, Ye K, De Jong R, Oltersdorf T, et al. Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions. J Biol Chem 2006; 281:31380-31388.
34. Reuter S, Elife S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008; 76:1340-1351.
35. Kelly E, Won A, Refaeli Y, Van Parijs L. IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 2002; 168:597-603.
36. Lenardo MJ, Fas and the art of lymphocyte maintenance. J Exp Med 1996; 183:721-724.
37. Snow AL, Oliveira JG, Zheng L, Dale JK, Fleisher TA, Lenardo MJ. Critical role for BIM in T cell receptor restimulation-induced death. Biol Direct 2008; 3:34.
38. Dewson G, Kluck RM. Bcl-2 family-regulated apoptosis in health and disease. Cell Health Cytoskeleton 2010; 2:9-22.
39. Bosque A, Marzo I, Naval J, Anel A. Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss. Mol Immunol 2007; 44:1446-1453.
40. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15:177-182.